Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC(neoSCORE)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.
Epistemonikos ID: ce776cc6440c47fd94daf090c07f75d309044db9
First added on: May 07, 2024